Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib plus paclitaxel for MET-altered advanced gastric and gastroesophageal junction cancer
KCT0006691Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tepotinib in gastric adenocarcinoma, esophagogastric junction cancer, sponsored by Merck & Co.. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
tepotinib
03
Conditions
gastric adenocarcinomaesophagogastric junction cancer
Beyond the preview
Go deeper on KCT0006691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006691.